ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 176,31
0,46%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Mind Medicine MindMed Inc (MNMD)

  7. Mind Medicine MindMed Inc (MNMD) Actualités

MNMD

Mind Medicine MindMed (MNMD)

Mind Medicine MindMed Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MNMD
DateHeureSourceTitreSymboleSociété
02/05/202413h00Business WireMindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business UpdateNASDAQ:MNMDMind Medicine MindMed Inc
25/04/202413h00Business WireMindMed to Present at Upcoming May Medical ConferencesNASDAQ:MNMDMind Medicine MindMed Inc
02/04/202413h00Business WireMindMed to Present at Upcoming April Medical ConferencesNASDAQ:MNMDMind Medicine MindMed Inc
01/04/202423h00Business WireMindMed Announces Voluntary Delisting from Cboe CanadaNASDAQ:MNMDMind Medicine MindMed Inc
11/03/202413h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNMDMind Medicine MindMed Inc
11/03/202412h00Business WireMindMed to Participate in the Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:MNMDMind Medicine MindMed Inc
07/03/202413h13Business WireMind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private PlacementNASDAQ:MNMDMind Medicine MindMed Inc
07/03/202413h09Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:MNMDMind Medicine MindMed Inc
07/03/202412h00Business WireMindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety DisorderNASDAQ:MNMDMind Medicine MindMed Inc
01/03/202419h56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNMDMind Medicine MindMed Inc
01/03/202415h00Business WireMindMed to Host Conference Call and Webcast to Discuss Data Update for MM120NASDAQ:MNMDMind Medicine MindMed Inc
29/02/202422h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNMDMind Medicine MindMed Inc
28/02/202413h20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MNMDMind Medicine MindMed Inc
28/02/202413h05Business WireMindMed Reports 2023 Financial Results and Business UpdatesNASDAQ:MNMDMind Medicine MindMed Inc
22/02/202413h00Business WireMindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results and Provide Business UpdateNASDAQ:MNMDMind Medicine MindMed Inc
07/02/202413h00Business WireMindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences ConferenceNASDAQ:MNMDMind Medicine MindMed Inc
08/01/202413h45Business WireMindMed Announces Business Update and Anticipated Milestones for 2024NASDAQ:MNMDMind Medicine MindMed Inc
14/12/202313h30Business WireMindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety DisorderNASDAQ:MNMDMind Medicine MindMed Inc
02/11/202321h20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNMDMind Medicine MindMed Inc
02/11/202321h01Business WireMindMed Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:MNMDMind Medicine MindMed Inc
26/10/202313h30Business WireMindMed to Host Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Business UpdateNASDAQ:MNMDMind Medicine MindMed Inc
24/10/202313h30Business WireMindMed Completes Enrollment of Phase 2a Trial of MM-120 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)NASDAQ:MNMDMind Medicine MindMed Inc
03/10/202313h30Business WireMindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) CongressNASDAQ:MNMDMind Medicine MindMed Inc
15/09/202323h27Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MNMDMind Medicine MindMed Inc
14/09/202313h30Business WireMindMed to Participate in the TD Cowen 3rd Annual Novel Mechanisms in Neuropsychiatry SummitNASDAQ:MNMDMind Medicine MindMed Inc
12/09/202313h30Business WireMindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)NASDAQ:MNMDMind Medicine MindMed Inc
28/08/202313h30Business WireMindMed to Participate at September Investor ConferencesNASDAQ:MNMDMind Medicine MindMed Inc
14/08/202313h30Business WireMindMed Secures $50.0 Million Credit Facility with K2 HealthVenturesNASDAQ:MNMDMind Medicine MindMed Inc
03/08/202322h01Business WireMindMed Reports Second Quarter 2023 Financial Results and Business HighlightsNASDAQ:MNMDMind Medicine MindMed Inc
03/08/202313h30Business WireMindMed Announces Exclusive License Agreement With Catalent for Its Patented Zydis® Fast-Dissolve Technology for Use with MM-120NASDAQ:MNMDMind Medicine MindMed Inc
 Showing the most relevant articles for your search:NASDAQ:MNMD

Dernières Valeurs Consultées

NYSE
KO
Coca Cola
EU
BN
Danone
EU
BEL20
Bel 20
EU
CS
Axa
EU
RI
Pernod Ricard
EU
VIV
Vivendi
NASDAQ
MSFT
Microsoft
EU
EN
Bouygues
EU
HO
Thales
NYSE
JPM
JP Morgan Chase
EU
AF
Air FranceKLM
EU
VK
Vallourec
EU
ML
Michelin
EU
LR
Legrand
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés